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INTRODUCTION 
Liposomes were discovered in the early 1960‟s by 
Bangham and collegue. The discovery of liposome or 
lipid vesicle emerged from self forming enclosed lipid 
bi-layer upon hydration. Liposomes, the phospholipid 
vesicles, are spherical lipid bilayers capable of 
entrapping water soluble solutes within an aqueous 
domains or alternatively lipid molecules within the lipid 
bilayers. They are biodegradable, biocompatible and 
non-immunogenic in nature, which makes them ideal 
drug carrier systems in therapeutics1.When 
phospholipids are dispersed in water, they spontaneously 
form closed structure with internal aqueous environment 
bounded by phospholipid bilayer membranes, this 
vesicular system is called as liposome2.Liposomes are 
the small vesicle of spherical shape that can be produced 
from cholesterols, non toxic surfactants, sphingolipids, 
glycolipids, long chain fatty acids and even membrane 
proteins3. Liposomes are the drug carrier loaded with 
great variety of molecules such as small drug molecules, 
proteins, nucleotides and even plasmids. Liposome can 
be formulated and processed to differ in size, 
composition, charge and lamellarity. To date liposomal 
formulations of anti-tumor drugs and antifungal agents 
have been commercialized 4. The clinical potential of 
liposomes as a vehicle for replacement therapy in genetic 
deficiencies of lysosomal enzymes was first 
demonstrated in 1970s 5, 6. Considerable progress was 
made during 1970s and 1980s in the field of liposome 
stability leading to long circulation times of liposomes 
after intravenous administration resulting in the 
improvement in bio-distribution of liposome. The 
important anti-tumour drug doxorubicin had been 
formulated as liposome in 1980s to improve the 
therapeutic index. Liposome research is gaining 
importance in biological, pharmaceutical and medical 
research because liposomes seem to be the most effective 
carriers for the introduction of all kinds of agents into 
cells7.The efficacy of liposomes as drug delivery systems 
would be increased dramatically if it were possible to 
deliver their contents selectively to particular cells or 
anatomical sites. Several types of liposomal formulations 
have been explored; such as those bearing carbohydrate 
determinants (lectins), monoclonal antibodies, 
glycoproteins and antigens with a view of targeting the 
liposomes to selective tissues or anatomical 
sites8,9.However, most of these formulations have failed 
to show any remarkable therapeutic efficacy because of 
several reasons such as antigenicity of the ligands, 
inability of the drug to reach the appropriate cellular 
compartment in active form and the presence of the 
endothelial or other histological barrier between the 
liposomes and its cellular binding site. These difficulties 
can be minimized by using temperature sensitive 
liposomes. These liposomes were developed by Yatvin et 
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al10 Weinstein et al. and others for better orientation to 
targeted sites. These liposomes are formed by a mixture 
of synthetic lipids such as   
dipalmitoylphosphatidylcholine (DPPC) and 
distearoylphosphatidylcholine (DSPC), that exhibits a 
gel to sol transition at temperature few degrees above the 
physiological temperature, a range easily obtainable by 
local hyperthermia. It was postulated that such liposomes 
would remain reasonably stable in the vascular system at 
the normal body temperature (37°C), and when passing 
through the heated area they would release their contents 
when the transition temperature is attained11,12,13. 
There are several mechanisms by which liposomes act 
within and outside the body which are as follows
 14
 
1- Liposome attaches to cellular membrane and appears 
to fuse with them, releasing their content into the 
cell. 
2-  2- Some times they are taken up by the cell and 
their phospholipids are incorporated into the cell 
membrane by which the drug trapped inside is 
released 
3-  3- In the case of phagocyte cell, the liposomes are 
taken up, the phospholipid walls are acted upon by 
organelles called lysosomes and the active 
pharmaceutical ingredients are released.[lectr11 note 
] 
 
ADVANTAGE OF LIPOSOMES 
 Provide controlled drug delivery  
 Biodegradable, biocompatible, flexible  
 Non ionic 
 Can carry both water soluble and lipid soluble drugs 
 Drug can be stabilized from oxidation  
 Controlled hydration  
 Improve protein stabilization  
 Provide sustained release  
 Targeted drug delivery and site specific drug 
delivery  
 Stabilization of   entrapped drug from hospital 
environment 
 Altered pharmacokinetics and pharmacodynamics     
 Can be administered through various route  
 Act as reservoir of drug  
 Therapeutic index of drug is increased  
 Site of avoidance therapy  
 Can modulated the destitution of drug 
  Direct interaction of drug with cell 
 
METHODS OF LIPOSOME FORMATION AND 
DRUG LOADING 
There are many ways of preparing lipososmes as listed 
below. Some of the important methods have been 
explained. 
1. Hydration of lipids in presence of solvent 
2. Ultrasonication 
3. French Pressure cell 
4. Solvent injection method 
a) Ether injection method 
b) Ethanol injection 
5. Detergent removal Detergent can be removed by 
a) Dialysis 
b) Coloumn chromatography 
c) Bio-beads 
6. Reverse phase evaporation technique 
7. High pressure extrusion 
8. Miscellaneous methods 
a) Slow swelling in Non electrolyte solution 
b) Removal of Chaotropic ion 
c) Freeze-Thawing 
Convectional method
15
 
In the procedure; the phospholipids are dissolved in an 
organic solvent (usually a chloroform/methanol mixture) 
and deposited from the solvents as a thin film on the wall 
of a round bottom flask by use of rotary  evaporation 
under reduced pressure. MLVs form spontaneously when 
an excess volume of aqueous buffer containing the drug 
is added to the dried lipid film. Drug containing 
liposomes can be separated from nonsequestered drug by 
centrifugation of the liposomes or by gel filtration. The 
time allowed for hydration of the dried film and 
conditions of agitation are critical in determining the 
amount of the aqueous buffer (or drug solution) that will 
be entrapped within the internal compartments of the 
MLVs. 
Sonication method
15
 
This method is used in the preparation of SUVs and it 
involves the subsequent sonication of MLVs prepared by 
the conventional method either with a bath type or a 
probe type sonicator under an inert atmosphere, usually 
nitrogen or argon. The principle of sonication involves 
the use of pulsed, high frequency sound waves (sonic 
energy) to agitate a suspension of the MLVs. Such 
disruption of the MLVs produces SUVs with diameter in 
the range of 15–50nm. The purpose of sonication, 
therefore, is to produce a homogenous dispersion of 
small vesicles with a potential for greater tissue 
penetration. The commonly used sonicators are of the 
bath and probe tip type. The major drawbacks in the 
preparation of liposomes by sonication include oxidation 
of unsaturated bonds in the fatty acid chains of 
phospholipids and hydrolysis to lysophospholipids and 
free fatty acids. Another drawback is the denaturation or 
inactivation of some thermolabile substances (e.g., DNA, 
certain proteins, etc) to be entrapped. 
High-pressure extrusion method
15
 
This is another method for converting MLV to SUV 
suspensions. By this method, suspensions of MLVs 
prepared by the convectional method are repeatedly 
passed through filters polycarbonate membranes with 
very small pore diameter (0.8–1.0μm) under high 
pressure up to 250psi. By choosing filters with 
appropriate pore sizes, liposomes of desirable diameters 
can be produced. The mechanism of action of the high 
pressure extrusion method appears to be much like 
peeling an onion. As the MLVs are forced through the 
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small pores, successive layers are peeled off until only 
one remains. Besides reducing the liposome size, the 
extrusion method produces liposomes of homogeneous 
size distributions. A variety of different lipids can be 
used to form stable liposomes by this method. Extrusion 
at low pressures <1Mpa is possible when lipid 
concentration is low, but the most commonly used 
pressures are about 5Mpa. A new technique uses 
10.5Mpa for better results. 
Solubilization and detergent removal method
15
 
This method is used in the preparation of LUVs and it 
involves the use of detergent (surfactant) for the 
solubilisation of the lipids. Detergents used include the 
non-ionic surfactants [e.g., n-octyl-bete-D-glucopyranose 
(octyl gluside), anionic surfactants (e.g., dodecyl 
sulphate) and cationic surfactants (e.g., 
hexadecyltrimethyl ammoniumbromide). The procedure 
involves the solubilisation of the lipids in an aqueous 
solution of the detergent and the protein(s) to be 
encapsulated. The detergent should have a high critical 
micelle concentration (CMC), so that it is easily 
removed. The detergent is subsequently removed by 
dialysis or column chromatography. During detergent 
removal, LUVs of diameter 0.08–0.2μm are produced. 
This detergent removal method has been found suitable 
for the encapsulation of proteins of biomedical 
importance. 
Reverse phase evaporation technique
15
 
It consists of a rapid injection of aqueous solution of the 
drug into an organic solvent, which contains the lipid 
dissolved with simultaneous bath sonication of the 
mixture leading to the formation of water droplets in the 
organic solvent (i.e., a “water-in-oil” emulsion). The 
resulting emulsion is dried down to a semi solid gel in a 
rotary evaporator. The next step is to subject the gel to 
vigorous mechanical agitation to induce a phase reversal 
from water-in-oil to oil-inwater dispersion (i.e., an 
aqueous suspension of the vesicles). During the agitation, 
some of the water droplets collapse to form the external 
phase while the remaining portion forms the entrapped 
aqueous volume. Large unilamellar vesicles (diameter 
0.1–1μm) are formed in the process. This method has 
been used to encapsulate both small and macromolecules 
such as RNA and various enzymes without loss of 
activity. The expected limitation of this method is the 
exposure of the material to be encapsulated to organic 
solvents and mechanical agitation, which can lead to the 
denaturation of some proteins or breakage of DNA 
strands. Reports of such limitations are however rare in 
the literatures. 
APPLICATIONS OF LIPOSOMES  
1. Applications of liposomes in medicine 
Applications of liposomes in pharmacology and 
medicine can be divided into therapeutic and diagnostic 
applications of liposomes containing drugs or various 
markers, and their use as a model, tool, or reagent in the 
basic studies of cell interactions, recognition processes, 
and of the mode of action of certain 
substances.Unfortunately many drugs have a very narrow 
therapeutic window, meaning that the therapeutic 
concentration is not much lower than the toxic one. In 
several cases the toxicity can be reduced or the efficacy 
enhanced by the use of an appropriate drug carrier which 
changes the temporal and spatial distribution of the drug, 
i.e. its pharmacokinetics and biodistribution16. 
A. Modes of liposome action 
Liposomes as drug delivery systems can offer several 
advantages over conventional dosage forms especially 
for parenteral (i.e. local or systemic injection or 
infusion), topical, and pulmonary route of administration. 
The preceding discussion shows that liposomes exhibit 
different biodistribution and pharmacokinetics than free 
drug molecules. In several cases this can be used to 
improve the therapeutic efficacy of the encapsulated drug 
molecules. The limitations can be reduced bioavailability 
of the drug, saturation of the cells of the immune system 
with lipids and potentially increased toxicity of some 
drugs due to their increased interactions with particular 
cells. The benefits of drug loaden liposomes, which can 
be applied as (colloidal) solution, aerosol, or in (semi) 
solid forms, such as creams and gels, can be summarized 
into seven categories: 
 (i) Improved solubility of lipophilic and amphiphilic 
drugs. Examples include Porphyrins, Amphotericin B, 
Minoxidil, some peptides, and  anthracyclines, 
respectively; furthermore, in some cases hydrophilic 
drugs, such as anticancer agent Doxorubicin or 
Acyclovir can be encapsulateded in the liposome interior 
at concentrations several fold above their aqueous 
solubility. This is possible due to precipitation of the 
drug or gel formation inside the liposome with 
appropriate substances encapsulated17; 
(ii) Passive targeting to the cells of the immune system, 
especially cells of the mononuclear phagocytic system 
(in older literature reticuloendothelial system). 
Examples are antimonials, Amphotericin B, porphyrins 
and also vaccines, immunomodulators or 
(immuno)supressors; 
(iii) Sustained release system of systemically or locally 
administered liposomes. Examples are doxorubicin, 
cytosine arabinose, cortisones, biological proteins or 
peptides such as vasopressin; 
(iv) Site-avoidance mechanism: liposomes do not 
dispose in certain organs, such as heart, kidneys, brain, 
and nervous system and this reduces cardio-, nephro-, 
and neuro-toxicity. Typical examples are reduced 
nephrotoxicity of Amphotericin B, and reduced 
cardiotoxicity of Doxorubicin liposomes; 
(v) Site specific targeting: in certain cases liposomes 
with surface attached ligands can bind to target cells 
(„key and lock‟ mechanism), or can be delivered into the 
target tissue by local anatomical conditions such as leaky 
and badly formed blood vessels, their basal lamina, and 
capillaries. Examples include anticancer, antiinfection 
and antiinflammatory drugs; 
(vi) Improved transfer of hydrophilic, charged molecules 
such as chelators, antibiotics, plasmids, and genes into 
cells. 
B. Conventional liposomes 
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For historical reasons we shall conventional liposomes 
distinguish between conventional liposomes and 
liposomes with altered surface properties. The first 
generation of liposomes includes various lipid 
compositions which changed the physicochemical 
properties of liposomes in a variety of different ways, but 
could not significantly alter their biological properties 
upon intravenous administration which is the most 
widely used route in medical applications. Therefore, the 
optimistic goals of antibody sensitised liposomes 
(immunoliposomes as „guided missiles‟), which gave 
often very encouraging results in in vitro studies – which 
are in general performed in the absence of 
immunoglobulins, complement components, and 
macrophages –failed in in vivo applications. The first 
condition for the immunoliposome concept  towork is 
therefore that they escape the clearance by the 
mononuclear phagocytic system. This was made possible 
by the introduction of sterically stabilized liposomes in 
which the presence of surface grafted hydrophilic 
polymers substantially prolongs the liposome blood 
circulation times, probably due to reduced interactions 
with the components of the immune system. This 
reduction arises from the presence of a steric barrier 
which prevents adsorption or hydrophobic binding of 
immune system components onto the foreign body. The 
liposomes with altered surfaces therefore include 
sterically stabilized liposomes and immunoliposomes. 
With respect to sterically stabilized immunoliposomes 
one should add a note of caution. Even liposomes with 
prolonged circulation in blood are not likely to be as 
widely applicable as many researchers envision(ed). The 
main limitations are extravasation (escaping from the 
blood circulation) and poor blood circulation in solid 
tumours. In the latter case, some of the particulates 
suspended in blood which come in the area extravasate 
due to leaky capillaries and stay or get stuck in the region 
of the extravasation and actually the presence of surface 
attached homing ligand, i.e. active targeting, does not 
really have much influence. In addition to some other 
targeting possibilities, such as injections in different 
body cavities immunoliposomes present a viable option 
in immunoassays and diagnostic tests16. 
i. Liposomes in parasitic diseases and infections 
Since conventional liposomes are digested by phagocytic 
cells in the body after intravenous administration, they 
are ideal vehicles for the targetting of drug molecules 
into these macrophages. The best knownM examples of 
this „Trojan horse-like‟ mechanism are several parasitic 
diseases which normally reside in the cell of 
mononuclear phagocytic system. They include 
leishmaniasis and several fungal infections. N 
Leishmaniasis is a parasitic infection of macrophages 
which affects over 100 million people in tropical regions 
and is often fatal. The efficacious dose of drugs, mostly 
different antimonials, is not much lower than the toxic 
one. Liposomes accumulate in the very same cell 
population which is infected and therefore offer an ideal 
drug delivery vehicle16. Indeed, the therapeutic index 
was increased in rodents as much as several hundred 
times upon administration of the drug in various 
liposomes. Surprisingly, and unfortunately, there was not 
much interest to scale up the formulations and clinically 
approve them after several very encouraging studies 
dating back to 1978. Only now, there are several ongoing 
studies with various antiparasitic liposome formulations 
in humans. These formulations use mostly ionophore 
Amphotericin B and are transplanted from very 
successful and prolific area of liposome formulations in 
antifungal therapy. The best results reported so far in 
human therapy are probably liposomes as carriers for 
Amphotericin B in antifungal therapies. This drug is the 
drug of choice in disseminated fungal infections which 
often parallel compromised immune system, 
chemotherapy, or AIDS and are frequently fatal. 
Unfortunately, the drug itself is very toxic and its dosage 
is limited due to its nephro- and neuro-toxicity. These 
toxicities are normally correlated with the size of the 
drug molecule or its complex and obviously liposome 
encapsulation prevents accumulation of drug in these 
organs and drastically reduces toxicity16. In addition, 
often the fungus resides in the cells of the mononuclear 
phagocytic system and therefore the encapsulation 
results in reduced toxicity and passive targetting. These 
benefits, however, can be associated with any colloidal 
drug carrier. Indeed, similar improvements in therapy 
were observed with microemulsions and stable mixed 
micellar formulations16.Furthermore, it seems that many 
of the early liposomal preparations were in fact liquid 
crystalline colloidal particles rather then selfclosed 
multilamellar liposomes. Since the lives of the first 
terminally ill  patients, which did not respond to all the 
conventional therapies, were saved16many patients were 
very successfully treated with a variety of Amphotericin 
B formulations. Similar approaches can be implemented 
in antibacterial, and antiviral therapy16.Most of the 
antibiotics, however, are orally available and liposome 
encapsulation can be considered only in the case of very 
potent and toxic ones which are administered 
parenterally. The preparation of antibiotics loaded 
liposomes at reasonably high drug to lipid ratios may not 
be easy because of the interactions of these molecules 
with bilayers and high densities of their aqueous 
solutions which often force liposomes to float as a 
creamy layer on the top of the tube. Several other routes, 
such as topical or pulmonary (by inhalation) are being 
considered also. Liposome encapsulated antivirals such 
as acyclovir, ribavarin, or azide thymidine (AZT) have 
also shown reduced toxicity and currently more detailed 
experiments are being performed with respect to their 
efficacy. 
ii. Macrophage activation and vaccination 
The automatic targetting of liposomes to macrophages 
can be exploited in several other ways, including the 
macrophage activation and in vaccination. Some natural 
toxins induce strong macrophage response which results 
in macrophage activation. This can be duplicated and 
improved by the use of liposomes because small 
molecules with immunogenic properties (haptens) cannot 
induce immune response without being attached to a 
larger particle. For instance, liposomes containing 
muramyl tripeptide, the smallest bacterial cell wall 
subunit with immunogenic properties cause macrophage 
activation. Activated macrophages are larger and contain 
more granulomae and lysosome material. 
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iii. Liposomes in anticancer therapy 
Many different liposome formulations of various 
anticancer agents were shown to be less toxic than the 
free drug18. Anthracyclines are drugs which stop the 
growth of dividing cells by intercalating into the DNA 
and therefore kill predominantly quickly dividing cells. 
These cells are in tumours, but also in gastrointestinal 
mucosa, hair, and blood cells and therefore this class of 
drugs is very toxic. The most used and  studied is 
Adriamycin (commercial name for Doxorubicin HCl). In 
addition to the above mentioned acute toxicities its 
dosage is limited by its cumulative cardiotoxicity. Many 
different formulations were tried. In most cases the 
toxicity was reduced about 50%. This includes both, 
short term and chronic toxicities because liposome 
encapsulation reduces the distribution of the drug 
molecules towards those tissues. For the same reason, on 
the other hand, the efficacy was in many cases 
compromised due to the reduced bioavailability of the 
drug, especially if the tumour was not phagocytic, or 
located in the organs of mononuclear phagocytic system. 
In some cases, such as systemic lymphoma, the effect of 
liposome encapsulation showed enhanced efficacy due to 
the sustained release effect, i.e. longer presence of 
therapeutic concentrations in the circulation 19while in 
several other cases the sequestration of the drug into 
tissues of mononuclear phagocytic system actually 
reduced its efficacy. Applications in man showed in 
general reduced toxicity, better tolerability of 
administration with not too encouraging efficacy. Several 
different formulations are in different phases of clinical 
studies and show mixed results20. 
iv. Other applications 
Small liposomes composed of lipids with long and 
saturated hydrocarbon chains in mixtures with 
cholesterol were shown to accumulate at the sites of 
inflammations. Such liposomes were used for diagnostic 
purposes21. They can also deliver anti-inflammatory 
drugs. Liposomes containing corticosteroids were 
injected also directly into the sites of inflammations, 
especially into arthritic joints where they acted as a 
sustained release system. Additionally, the contamination 
of healthy tissues with drug molecules was reduced. 
Liposomes can be used also to deliver drugs into the lung 
22. This is most often done by inhalation of liposome 
aerosol. This can be used either for the treatment of 
various lung disorders, infections, asthma, or using lungs 
as a drug depot for the systemic delivery.One of the 
possible applications of these aerosols is in the asthma 
relief in which the dosing frequency can be substantially 
reduced and single inhalation can last overnight23. The 
natural fate of liposomes to accumulate in liver and 
spleen was exploited in the treatment of neonatal 
jaundice in an animal model24. The application of free 
and liposomal metalloporphyrins which inhibit enzyme 
which breaks down hemoglobin into toxic bilirubin, 
however, did not result in statistically significant 
reduction of the enzyme activity. This is probably due to 
the fact that uptake by liver greatly exceeds the uptake 
into the spleen in which the degradation takes place. 
However, when the liver uptake was presaturated with a 
dose of empty liposomes, the enzymatic activity was 
significantly reduced due to targetting of liposomes to 
the spleen24. Liposomes can be applied also as a thick 
cream, gel, or tincture. In addition to subcutaneous or 
intramuscular drug depot these formulations can be 
applied topically. Several researchers claim increased 
penetration of lipid and drug molecules into the skin. 
These data, as well as possible mechanisms, are, 
however, still a matter of controversy. Oral applications 
of liposomes are at present rather limited due to the very 
liposomicidal environment in stomach and duodenum 
and normally the administration of free or liposome 
encapsulated drug exhibits usually no differences. 
Intragastrical administration, however, shows that 
liposomes enhance the systemic bioavailability of certain 
water insoluble drugs and vitamins. Several designs to 
stabilize liposomes in low pH, degradative enzyme, and 
bile salts containing environments are being studied. 
They include liposomes composed from many bilayers 
with different chemical stability and with programmable 
degradation kinetics, liposome encapsulated in 
biodegradable gels or capsules, polymer coated 
liposomes, and similar. More research is needed, 
however, to find out if some of these approaches are 
commercially viable. 
C. Liposomes with altered surface properties 
All these applications have made use of the so-called 
conventional liposomes. New strategies, including 
selective targetting of cancer and other diseased cells, 
however, rely on liposomes with altered surface 
properties. For selective interactions with particular cells, 
liposomes have to bear surface attached antigens. The 
application of these immunoliposomes, however, suffers 
from their quick clearance from the blood by the immune 
system and their inability to extravasate, i.e. leave the 
blood stream. These two limitations can be bypassed in 
certain applications, such as in treatments of 
intraperitoneal tumours or other disorders, in the use of 
liposomes as localized drug reservoir, in some topical 
applications, or in pulmonary applications of liposome 
aerosols, but for the majority of other applications the 
fast clearance represents the major obstacle. For this 
reason sterically stabilised liposomes were introduced 
which can largely avoid detection by the immune system 
and were shown to have blood circulation times for 
several days (half lives in humans > 2 days as compared 
to minutes rather than hours of conventional liposomes). 
For this reason they are often called Stealth liposomes. 
Of course only with stealth immunoliposomes, systemic 
active targetting became a possibility16. 
 Sterically stabilised liposomes 
The fate of liposomes, i.e. their rapid clearance from the 
body, was realized rather early. First attempts to alter 
their biodistribution by either surface ligands or 
membrane composition were undertaken in the late 70‟s. 
The results showed that liposome disposition can be 
altered, but predominantly within the mononuclear 
phagocytic system including the intrahepatic uptake 
itself. Blood circulation times were prolonged but the 
first substantial improvements were achieved by the 
incorporation of ganglioside GM1 or 
phosphatidylinositol at 5–10 mol% into the bilayer. The 
best results were obtained by substituting these two 
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lipids with synthetic polymer containing lipids. The 
longest circulation times were achieved when 
polyethylene glycol covalently bound to the 
phospholipid was used. It seems that intermediate 
molecular weights, from 1500 to 5000 Da are the 
optimum .The origin of steric stabilisation is well 
documented although not well understood. It was shown 
that the Alexander-de-Gennes model of polymers at 
interfaces can qualitatively explain the stability of 
liposomes in biological systems. The model can explain 
minimal polymer concentration above the surface of the 
bilayer at which polymer forms the so-called brush 
conformation and which acts as a steric shield. Small 
angle X-ray scattering measurements of force-distance 
profiles of polyethylene glycol grafted liposomes have 
shown enhanced bilayer repulsion in agreement with the 
hypothesis that reduced surface adhesion and adsorption 
stabilises liposomes. Recent theoretical work also 
explained the experimentally well known fact that 
increased concentrations of longer chains start to reverse 
the effect at particular polymer density16. This is due to 
the so-called collapse of the brush which occurs at 
certain polymer density and results in polymer self 
aggregation, a well known fact from the experimental 
polymer science. Longer chains can also exhibit 
increased attractive and bridging forces with 
macromolecules. Of course, the in vivo and in vitro 
stability are not necessarily correlated and, for example, 
in vitro very stable formulations, such as highly charged 
ones, or the ones with charged brush, are cleared in vivo 
very rapidly. Another factor which may differ between 
the two tests is the role of chain flexibility on the 
interactions with particles and proteins. It is possible that 
the decreased mobility of chains in the denser brush 
regimes, when the chain motion correlation times may 
approach times required for protein binding, can account 
for the weak physisorption of proteins16. 
 Medical applications of stealth liposomes 
Sterically stabilised vesicles can act either as long 
circulating microreservoirs or tumour (or site of 
inflammation and infection) targetting vehicles. The 
former applications requires larger liposomes (~ 0.2 µm) 
while the latter one is due to the ability of small vesicles 
to leave the blood circulation. The prolonged presence of 
small particulates in blood results in effective 
extravasation in regions with porous, damaged, or badly 
formed blood vessels which often characterize tumours 
or their vicinity. While normal molecules and 
macromolecules quickly come to equilibrium large doses 
of liposomes can accumulate due to their adhesion or 
immobilization. (In analogy with biocompatible surfaces 
we can speculate that PEG chains effectively reduce the 
adsorption of proteins while for the prevention of cell 
adhesion much longer chains would be required16. At 
present, it is still not known if such long chains can be 
effectively incorporated into liposomes.) This allows 
larger doses of liposome loaded drugs to be delivered to 
malignant tissues. For instance more then 10% of the 
injected dose of stealth liposome encapsulated 
Doxorubicin was found in tumours25 as opposed to 
around 1% when free drug was administered. Extensive 
liposome localization in the tumors was observed. 
Healthy tissue did not accumulate any signal which was 
due to Doxorubicin fluorescence16. Efficacy studies in 
various mice tumour models, such as implanted solid 
C26 carcinoma and inoculated mammary carcinoma, 
have shown dramatic improvements26,30. Solid C26 colon 
tumour is practically ~Doxorubucin) liposomes, and 
mixtures of free drug and empty stealth liposomes. 
Stealth Epirubicin and Doxorubicin liposomes resulted, 
however, in complete remissions of tumors in the early 
treatment schedule and substantial reduction of tumour 
size in the delayed treatment regime27.Similar 
improvement in therapy was observed also in mammary 
carcinoma28.These formulations were substantially more 
effective not only in curing mice with recent implants 
from various tumors but also in reducing the incidence of 
metastases originating from these intra mammary 
implants. Similarly, several fold increased drug 
accumulation was observed also in sites of infections 
which are also characterized by the enhanced vascular 
permeability. For instance, in mice with infected lungs 
10 fold more antibiotic drug accumulated in the infected 
lung as compared to the noninfected one29. Sterically 
stabilised liposomes may act also as a sustained drug 
release system either as a long circulating microreservoir 
or localised drug depot. The first example is provided by 
improved therapeutic efficacy of cytosine arabinose in 
the treatment of lymphoma30 while the 
subcutaneous/intramuscular sustained release system was 
demonstrated by the action of polypeptide vasopressin 32. 
Its action was prolonged up to a month as compared to 
few days for a free drug and a week for the peptide 
encapsulated in conventional liposomes. It is important 
to note that these concepts are becoming more and more 
important with the introduction of genetically engineered 
polypeptides and proteins which are hampered by the 
rapid blood clearance, degradation and/or deactivation in 
the body. The altered biodistribution of stealth 
liposomes, in addition to the accumulation at the sites 
characterised with porous blood capillaries, such as in 
tumours, inflammations, and infections, may benefit 
several other applications. In the intact vasculature the 
distribution of stealth liposomes is shifted from the liver, 
spleen, and bone marrow towards skin. This opens the 
opportunity to deliver antivirals and dermatological 
agents to these sites. On the other hand, and while it was 
shown that the administration of empty stealth liposomes 
is well tolerated
16
,it requires careful toxicology and 
tolerability studies when liposomes loaden with potent 
drugs are used.  
 Applications of Stealth liposomes in man 
The encouraging results of Doxorubicin encapsulated in 
Stealth liposomes in preclinical studies were observed 
also in clinical trials in humans. Blood circulation times 
around 45 hours were found 33 and at reduced toxicity 
very good response in AIDS patients with Kaposi 
sarcoma was observed34,35. Long circulation times 
significantly, i.e. 200-fold, increased the area under 
curve of drug concentration vs time and accumulation in 
various tumours was proportional to the liposome 
circulation times34. The drug remained encapsulated in 
circulating liposomes up to one week after injection 
while at tumour sites drug metabolites were found 
indicating that it had been released from liposomes. The 
concentration of the drug in tumours was 4–10 times 
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greater than in control group which was treated with free 
drug33. The same selective targeting was observed also in 
patients with Kaposi sarcoma. Practically all patients 
showed considerable decrease in modularity of skin 
lesions while total flattening was observed in 25% of the 
cases34. The high efficacy was due to the approximately 
ten fold higher drug concentration in lesions as compared 
to the administration of free drug 35. In conclusion, it 
seems that stealth liposomes loaded with anticancer 
drugs will achieve substantial improvements in the 
treatments of various tumours. In addition, it is hoped 
that they will be effective also in the treatments of 
inflammations, infections, and in antiviral therapy. 
2. Liposomes in bioengineering 
Modern genetic engineering and gene recombinant 
technology is based on the delivery of genetic material, 
i.e. fragments of DNA, into various cells and 
microorganisms in order to alter their genetic code and 
force them to produce particular proteins or 
polypeptides36. Nucleic acids used in gene transfer are 
large, with molecular weights up to several million 
Daltons, highly charged and hydrophilic and therefore 
not easy to transfer across cell membranes. Additionally 
to classical methods, such as direct injection, phosphate 
precipitation and others, liposomes were tried as 
transfection vectors. They can deliver the encapsulated 
or bound nucleic acid into cells predominantly in two 
ways: the classical approach is to encapsulate the genetic 
material into liposomes and liposomes act as an 
endocytosis enhancer while recently the phosphate or 
DEAE precipitation was simulated by liposomes. In 
these cases the nucleic acid forms a complex with several 
cationic liposomes and the size of the complex and its 
adsorption on the cell surface catalyses endocytosis or, 
possibly, fusion. The third, still unexplored way would 
be to use fusogenic liposomes or cause fusion upon 
adsorption of the liposome on the cell surface. The 
classical approach used predominantly large unilamellar 
vesicles made from negatively charged 
phosphatidylserine in order to prevent interaction with 
DNA molecules which may contain up to several 
thousand negative charges37. In some cases transfection 
efficiencies were improved several hundred times and 
plant protoplast which are very difficult to transfect were 
successfully genetically altered
38
. In the mid 80‟s, 
however, electroporation showed better results and the 
interest for liposomes markedly diminished. Recently, 
however, transfection was successfully performed using 
small unilamellar vesicles made from positively charged 
lipids. First studies used cationic lipid dioleoyl-propyl-
trimethylammonium (DOTMA)[57]. Later studies 
showed better transfection efficiencies by using some of 
the commercially available cationic lipids40. Better 
transfection efficiencies at reduced toxicity were found 
by using liposomes containing positively charged 
cholesterol 41. Many novel cationic lipids are being 
synthetised in order to improve transfection, especially in 
vivo. These methods can be used also in gene therapy. 
The idea is to deliver the nondefective gene into the 
appropriate cells and hope that they will respond. For 
instance, patients with cystic fibrosis have a defective 
gene that encodes the code for a protein critical to a 
transfer of salts through the cell membrane in the lungs. 
In recent experiments, upon inhalation of the copies of 
human gene mixed with liposomes, 70% of the cells 
lining the lungs of mice incorporated the gene and began 
using it to make proteins in large amounts 42. This 
promises elimination or drastic reduction of the 
symptoms of the disease if it can be repeated in humans. 
3. Application of Liposomes in cosmetics  
In general the rules for topical drug applications and 
delivery of other compounds are less stringent than the 
ones for parenteral administration and several hundred 
cosmetic products are commercially available since 
Capture (C. Dior) and Niosomes (L‟Or´eal) were 
introduced in 1987. They range from simple liposome 
pastes which are used as a replacement for creams, gels, 
and ointments for do-it-yourself cosmetical products to 
formulations containing various extracts, moisturizers, 
antibiotics, and to complex products containing 
recombinant proteins for wound or sunburn healing. 
Most of the products are anti-ageing skin creams. 
Unrinsable sunscreens, long lasting perfumes, hair 
conditioners, aftershaves and similar products, are also 
gaining large fractions of the market. Liposomal skin 
creams already share more than 10% of the over $10 
billion market. As in the case of topical delivery in 
medical applications, the workers in the field do not 
agree on the mechanism of action. While some claim 
enhanced permeability into the skin the others claim 
mostly that liposomes are a noninteractive, skin-
nonirritating, water based matrix (without alcohols, 
detergents, oils and other non-natural solubilizers) for the 
active ingredients16. 
4. Application of liposomes in agro-food industry 
The ability of liposomes to solubilize compounds with 
demanding solubility properties, sequester compounds 
from potentially harmful milieu, and release incorporated 
molecules in a sustained and predictable fashion can be 
used also in the food processing industry. Lipid 
molecules, from fats to polar lipids, are one of the 
fundamental ingredients in almost any food. For 
instance, lecithin and some other polar lipids are 
routinely extracted from nutrients, such as egg yolks or 
soya beans. Traditionally polar lipids were used to 
stabilize water-in-oil and oil-in-water emulsions and 
creams, or to improve dispersal of various instant 
powders in water. With the advent of microencapsulation 
technology, however, liposomes have become an 
attractive system because they are composed entirely 
from food acceptable compounds. The sustained release 
system concept can be used in various fermentation 
processes in which the encapsulated enzymes can greatly 
shorten fermentation times and improve the quality of 
the product. This is due to improved spatial and temporal 
release of the ingredient(s) as well as to their protection 
in particular phases of the process against chemical 
degradation. A classical example is cheese making. The 
first serious attempts to decrease the fermentation time 
using cell-wall-free bacterial extracts were encouraging 
enough to stimulate efforts to improve enzyme 
presentation. After preliminary studies in which 
liposome systems were optimized the cheese ripening 
times can be shortened by 30–50%43,45. This means a 
substantial economic profit knowing that ripening times 
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of some cheeses, such as Cheddar, say, are about one 
year during which they require well controlled 
conditions. In addition, due to the better dispersal of the 
enzymes the texture of cheeses was even and bitterness 
and inconsistent flavour due to the proteolysis of 
enzymes in the early phase of fermentation was much 
improved43,44. In addition to improved fermentation, 
liposomes are being tried in the preservation of cheeses. 
Addition of nitrates to cheese milk to suppress the 
growth of spore-forming bacteria is now being 
questioned due to health concerns and natural 
alternatives are under study. Lysozyme is effective but 
quickly inactivated due to binding to cassein. Liposome 
encapsulation can both preserve potency and increase 
effectiveness because liposomes become localized in the 
water spaces between the casein matrix and fat globules 
of curd and cheese. This also happens to be where most 
of the spoilage organisms are located45. These 
applications of enhancing natural preservatives, 
including antioxidants such as vitamins E and C, will 
undoubtedly become very important due to recent dietary 
trends which tend to reduce the addition of artificial 
preservatives and ever larger portion of unsaturated fats 
in the diet. In other areas of the agro-food industry, 
liposomes encapsulated biocides have shown superior 
action due to prolonged presence of the fungicides, 
herbicides or pesticides at reduced damage to other life 
forms 46. Liposome surface can be made sticky so that 
they remain on the leafs for longer times and they do not 
wash into the ground. In these applications inexpensive 
liposomes produced from synthetic lipids are used. The 
same liposomes are being tried in shellfish farms. These 
animals are susceptible for many parasitic infections. 
They are filtermfeeders and they pump large amounts of 
water through their body. This seems to offset large 
dilutions of liposomes in the pool and the drug molecules 
as well as some essential nutrients needed in ppm to ppb 
quantities can be delivered. 
5. Other applications of liposomes 
The potential of making large quantities of inexpensive 
and stable liposomes may put forward several other 
applications. They range from water based paints, single 
tube two component glues or resins, self healing paints, 
and similar products. They are based mostly on the 
dissolving potential of liposomes and their ability to 
protect the encapsulated substance until an external 
stimulus such as the presence of oxygen, light, or change 
in hydration. Critical evaluation of these applications is 
difficult, however, because the information is mostly 
concentrated in progress reports, business analyses, or 
prospectuses of various producers. In ecology, liposomes 
offer improvements in bioreclamation and various 
monitoring and analytical-diagnostic applications. For 
instance, it was shown that in an oil spill, the addition of 
various bacteria with possible nutrients encapsulated in 
liposomes improves the degradation rates of 
carbohydrates, which are otherwise very slow. Due to the 
surfactant action liposomes also improve the coagulation 
and sinking of oil spread on the water surface or its 
cleaning up with floating booms. The Environmental 
Protection Agency is testing liposomes‟ ability to deliver 
nutrients to oil spills to speed up the degradation. 
Liposomes containing membrane anchored chelators can 
be used to clean toxic or radioactive metals from 
solutions. For instance, water contaminated in a nuclear 
reactor can be purified by addition of such liposomes 
which could be easily precipitated after binding of the 
toxic ions. In addition to the above mentioned liposome 
applications there are many others which were not 
mentioned. Despite over a 1 billion dollar cosmetic 
liposome industry, I dare to say that the real future of 
liposomes is in anticancer and possibly other 
chemotherapies, gene therapy as well as some other 
medical applications such as artificial blood16. 
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